Nvidia Corp vs Viatris Inc — how do they compare? Nvidia Corp trades at $223.18 (market cap $5.45T), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Nvidia Corp is far larger — about 285.5× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| NVDA | VTRS | |
|---|---|---|
Market Cap | $5.45T | $19.09B |
Sector | Technology | Health |
52-Week High | $235.75 | $17.86 |
52-Week Low | $165.17 | $9.49 |
Enterprise Value | $5.43T | $31.21B |
Dividend Yield | 0.44% | 2.89% |
Signals from Pluang's Aura AI — not financial advice
NVIDIA (NVDA) trades at $225.73, down 2.01% over the past day, amid a broader tech sell-off. The stock maintains a bullish technical signal with strong moving average support, while oscillators are neutral. Fundamentally, the company reported robust revenue of $130.50B in 2025, with net income surging to $72.88B, reflecting a 55.84% profit margin. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.22 surpassing the $2.09 estimate. Analyst sentiment remains overwhelmingly positive, with a consensus price target of $344.10 implying significant upside.
Outlook: NVDA's leadership in AI chips and accelerating revenue growth present a compelling investment case, though risks include heightened competition and potential market saturation. The stock's current valuation metrics, such as a P/E of 28.54, appear reasonable given its growth trajectory. Institutional ownership trends and strong cash flow generation support long-term bullish sentiment, but investors should monitor execution risks and macroeconomic headwinds.
Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.
The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.
Trailing returns across standard periods
Latest headlines on both assets
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →